Effects of nafarelin on bone density.

Area of Science:

• Reproductive Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Endometriosis affects premenopausal women, impacting quality of life.
• Gonadotropin-releasing hormone (GnRH) analogs are used to treat endometriosis.
• The impact of GnRH analogs on bone metabolism requires careful evaluation.

Purpose of the Study:

• To assess the effects of nafarelin, a GnRH analog, on bone metabolism in premenopausal women with endometriosis.
• To compare the effects of different nafarelin dosages on bone mineral density and resorption.
• To evaluate bone mineral recovery after nafarelin treatment cessation.

Main Methods:

• Two studies were conducted, each involving 6 months of nafarelin treatment followed by 6 months of observation.
• Bone mineral measurements and bone resorption markers were assessed.
• A second study compared nafarelin with norethindrone combination therapy.

Main Results:

• Low-dose nafarelin (200 mcg/day) maintained bone mineral measurements.
• High-dose nafarelin (400 mcg/day) led to significant decreases in bone mineral levels and increased bone resorption.
• Bone mineral levels and resorption returned to baseline within 6 months after discontinuing nafarelin.
• Combination therapy with nafarelin (400 mcg/day) and norethindrone (1.2 mg/day) did not result in significant bone mineral loss.

Conclusions:

• Nafarelin's effect on bone metabolism is dose-dependent.
• Bone mineral density loss associated with high-dose nafarelin is reversible upon treatment cessation.
• Combination therapy with norethindrone may mitigate bone loss during endometriosis treatment.